AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05158517
Drug: Subcutaneous vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
Trial: NCT04935073
Drug: Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
Trial: NCT05266417
Drug: INS-GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal INS-GSH Twice Daily
Trial: NCT04467086
Drug: Propranolol Hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min.
Trial: NCT05096065
Drug: Leuprolide Oral Tablet - 120 mg - QD- Treatment A
RxNorm normalized name: leuprolide acetate 120 MG/ML
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions.
Trial: NCT05096065
Drug: Leuprolide Oral Tablet - 80 mg - QD - Treatment B
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.
Trial: NCT05096065
Drug: Leuprolide Oral Tablet - 60 mg - QD - Treatment C
RxNorm normalized name: leuprolide acetate 60 MG/ML
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For up to 29 consecutive days with food-intake restrictions
Trial: NCT05096065
Drug: Leuprolide Oral Tablet - 60 mg - BID - Treatment D
RxNorm normalized name: leuprolide acetate 60 MG/ML
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.
Trial: NCT05096065
Drug: Leuprolide Oral Tablet - 40 mg - BID - Treatment E
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For up to 29 consecutive days with food-intake restrictions
Trial: NCT05019417
Drug: Glycerol Phenylbutyrate 1100 MG/ML
RxNorm normalized name: glycerol phenylbutyrate 1100 MG/ML
DrugBank: Glycerol phenylbutyrate (DB08909)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
Trial: NCT05667454
Drug: Atropine Ophthalmic 0.5%
RxNorm normalized name: atropine ophthalmic 0.5% ophthalmic solution
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 0.5% sulphate ophthalmic solution
Trial: NCT05781074
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a PD-1 immune checkpoint inhibitor
Trial: NCT05781074
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules
Trial: NCT05045261
Drug: administration of SLGN in arm C
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 3mg SLGN weekly for 24 weeks in arm C
Trial: NCT05379491
Drug: 3 L PEG + linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
Trial: NCT05379491
Drug: 3 L PEG + placebo
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
Trial: NCT05064371
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concentrate for solution for IV infusion
Trial: NCT05184517
Drug: Restasis
RxNorm normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
Trial: NCT05287386
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
Trial: NCT05705466
Drug: Navtemadlin
RxNorm normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Trial: NCT05705466
Drug: Navtemadlin Placebo
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
Trial: NCT05705466
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
Trial: NCT05254171
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel protein-bound particles for injectable suspension
Trial: NCT05254171
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine for injection
Trial: NCT05375825
Drug: LMB-100
RxNorm normalized name: LMB-100
DrugBank: LMB-100 (DB18591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
Trial: NCT05067387
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral THC (20 mg)
Trial: NCT05067387
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral CBD (20 mg)
Trial: NCT05165082
Drug: Timolol maleate 0.5% ophthalmic solution
RxNorm normalized name: Timolol Maleate 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply on affected finger or toes twice daily for 8 weeks
Trial: NCT05325853
Drug: AG-920
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-920 Sterile Topical Ophthalmic Solution
Trial: NCT00002394
Drug: Terbinafine hydrochloride
RxNorm normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00033163
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00033163
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05375240
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
Trial: NCT05375240
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously 2.0g/day for 7 consecutive days.
Trial: NCT06389578
Drug: Teprotumumab
RxNorm normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SC administration and IV infusion
Trial: NCT05677633
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Trial: NCT04917731
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botox injected at digital artery
Trial: NCT05062577
Drug: buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sublingual
Trial: NCT05817409
Drug: Intrathecal Baclofen Pump
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal baclofen treatment
Trial: NCT05441267
Drug: Semaglutide Oral Tablet
RxNorm normalized name: semaglutide Oral Tablet
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral semaglutide 14mg daily (option to reduce to 7mg daily)
Trial: NCT05173896
Drug: Tadalafil 20 MG
RxNorm normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
Trial: NCT04465734
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
Trial: NCT04465734
Drug: HLX04
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
Trial: NCT04465734
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
Trial: NCT06726382
Drug: Esketamine Nasal Spray
RxNorm normalized name: esketamine Nasal Spray
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 28 mg dose
Trial: NCT06726382
Drug: Esketamine 28 mg
RxNorm normalized name: esketamine 28 mg nasal spray
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 x 5,6 ml p.o.
Trial: NCT06726382
Drug: Cobicistat 150 MG
RxNorm normalized name: cobicistat 150 MG
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 150 mg tablet
Trial: NCT06725992
Drug: IY-NT-SR
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10mg
Trial: NCT03915613
Drug: Humulin R
RxNorm normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Trial: NCT03915613
Drug: Diluent
RxNorm normalized name: Diluent
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Trial: NCT06725771
Drug: Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline
RxNorm normalized name: oyster shell calcium carbonate preparation
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
Trial: NCT06725771
Drug: Sertraline Hydrochloride Tablets
RxNorm normalized name: Sertraline Hydrochloride Tablets
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline are given to patients simultaneously
Trial: NCT05639257
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine tablets increasing dosis to maximal 300 mg daily
Trial: NCT05639257
Drug: Namuscla
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Namuscla tablets increasing dosis to maximal 501 mg daily
Trial: NCT06392633
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
Trial: NCT05488925
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evion, 400 mg
Trial: NCT05618236
Drug: Group N; neostigmine+atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
Trial: NCT05618236
Drug: GROUP S; decurarized with sugammadex.
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
Trial: NCT05488925
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramal, 50 mg
Trial: NCT04775953
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
Trial: NCT04775953
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
Trial: NCT04775953
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
Trial: NCT04775953
Drug: Nafcillin
RxNorm normalized name: Nafcillin
DrugBank: Nafcillin (DB00607)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
Trial: NCT04775953
Drug: Oxacillin
RxNorm normalized name: Oxacillin
DrugBank: Oxacillin (DB00713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
Trial: NCT04775953
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
Trial: NCT05215925
Drug: HLX07+carboplatin+pemetrexed
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HLX07 1500mg q3w+carboplatin+pemetrexed
Trial: NCT05215925
Drug: HLX07+docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HLX07 1500mg q3w+docetaxel
Trial: NCT05215925
Drug: HLX07
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 1500mg q3w
Trial: NCT05065359
Drug: Rodatristat Ethyl 300 mg BID
RxNorm normalized name: Ethyl acetate
DrugBank: Rodatristat (DB18478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 300 mg, BID 14 days
Trial: NCT05065359
Drug: Rodatristat Ethyl 600 mg BID
RxNorm normalized name: Ethyl acetate
DrugBank: Rodatristat (DB18478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 600 mg, BID 14 days
Trial: NCT01522092
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg-20mg, tablet, od, 12 months
Trial: NCT04738981
Drug: UC-MSC
RxNorm normalized name: UC-MSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
Trial: NCT04738981
Drug: Anti-CD25 mAb
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
Trial: NCT05257798
Drug: IFN-β inhibitor treatment
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
Trial: NCT04839016
Drug: SHR-1314
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1314